CD8A and neoplasm: Approximately 50 days after surviving in vivo, the tumor-infiltrating CD8+ MUC28z CAR T cells expressed very high levels of CD25 as well as PD1 (Figure 5C), suggesting their further activation by in vivo tMUC1 tumor antigen stimulation.